WO2023062545 - PEPTIDES AND FRAGMENTS FOR TREATING DIABETES AND ASSOCIATED METABOLIC DISEASES
National phase entry:
Publication Number
WO/2023/062545
Publication Date
20.04.2023
International Application No.
PCT/IB2022/059757
International Filing Date
11.10.2022
Title **
[English]
PEPTIDES AND FRAGMENTS FOR TREATING DIABETES AND ASSOCIATED METABOLIC DISEASES
[French]
PEPTIDES ET FRAGMENTS POUR LE TRAITEMENT DU DIABÈTE ET DE MALADIES MÉTABOLIQUES ASSOCIÉES
Applicants **
BETAVIVE LTD.
5 Nahum Het Street
Topaz Building, MATAM Center
31905 Haifa, IL
Inventors
PALTI, Yoram
51 Ruth Street
34404 Haifa, IL
ZURI, Dotan
13 Alon St.
2018300 Shekhanya, IL
Priority Data
63/254,738
12.10.2021
US
63/294,221
28.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2193 | |
| EPO | Filing, Examination | 12603 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 16910 |
Total: 32904 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The disclosure provides for peptides, fragments, compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 1 diabetes, type 2 diabetes). In some aspects, methods comprise administering peptides, fragments, or a variant thereof to the subject for treating diabetes and diseases related to diabetes. In other aspects, compounds, compositions, and methods containing IGF‐2 or variants thereof, IGF‐2 peptides, and IGF‐2 fragments are used for treating a disorder in a patient in need thereof, such as type 1 or type 2 diabetes.[French]
La présente divulgation concerne des peptides, des fragments, des composés, des compositions et leurs méthodes d'utilisation pour le traitement du diabète (p. ex., du diabète de type 1 ou de type 2). Dans certains aspects, les méthodes comprennent l'administration de peptides, de fragments ou d'une variante de ceux-ci au sujet pour le traitement du diabète et de maladies associées au diabète. Dans d'autres aspects, des composés, des compositions, et des méthodes comprenant IGF-2 ou des variants de celui-ci, des peptides d'IGF-2 et des fragments d'IGF-2 sont utilisés pour traiter un trouble chez un patient le nécessitant, tel que le diabète de type 1 ou de type 2.